Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)
Maze Therapeutics (MAZE) posted Preferred Stock Liabilities of $508.1 million for Q4 2024, up 32.35% sequentially from $383.9 million in Q3 2024.
Powered by 
Analysis
Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024) Analysis & Trends
Maze Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $508.1 million in Q4 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $508.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $508.1 million (changed N/A YoY) and the FY2024 annual result came in at $508.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $508.1 million in Q4 2024 per MAZE's latest filing, from $383.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $508.1 million in Q4 2024 and troughed at $383.9 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 508.09 Mn |
| Sep 30, 2024 | 383.90 Mn |
| Jun 30, 2024 | 383.90 Mn |
| Mar 31, 2024 | 383.90 Mn |